Caricamento...
Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma
The expression of CD30 receptors is one of the defining characteristics of the malignant Reed-Sternberg cells of Hodgkin lymphoma. CD30 is rarely expressed by normal cells, and is rapidly internalized, making it an ideal therapeutic target for monoclonal antibodies and for antibody-drug conjugates (...
Salvato in:
| Pubblicato in: | Cancer J |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2016
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5042201/ https://ncbi.nlm.nih.gov/pubmed/26841013 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PPO.0000000000000168 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|